2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Multiple Sclerosis
2
Skin Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Multiple Sclerosis, Relapsing-Remitting
1
Multiple Sclerosis, Chronic Progressive
1
Multiple Myeloma
1
Melanoma
1
Carcinoma, Basal Cell
1
Interventions
fludarabine
4
Cyclophosphamide
4
Specimen Handling
2
Nivolumab
2
Natalizumab
2
Interferon beta-1b
2
Fingolimod Hydrochloride
2
Blood Specimen Collection
2
teriflunomide
1
nabiximols
1
gadobutrol
1
gadobenic acid
1
cabozantinib
1
Surveys and Questionnaires
1
Respiratory Therapy
1
Registries
1
Platinum Compounds
1
Platelet Transfusion
1
Plasma Exchange
1
Phlebotomy
1
OM 89
1
Mn-PyC3A
1
Medical Marijuana
1
Magnetic Resonance Spectroscopy
1
Magnetic Resonance Imaging
1
Ipilimumab
1
Interferon beta-1a
1
Injections
1
Gadolinium DTPA
1
Fish Oils
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Multiple Sclerosis
×
Natalizumab
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled
NCT01416181
2017-09-11
ASCEND in SPMS
Biogen
Phase 3
Terminated
889 enrolled
31 charts